Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following patent update:
NXP002
NXP002 is the Company’s lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (“IPF”) for which the Company holds multiple patents:
· NXP002 Substance of Matter: Following grants in the US and Japan, the European Patent Office formally issued a grant of patent number 3837238 on 12 June 2024 covering the Company’s proprietary NXP002 drug forms being progressed by the Company as a potential novel IPF treatment.
· NXP002 Method of Use: The US PTO issued a grant of patent application 17/365,490 on 14 June 2024, covering use of the Company’s proprietary drug forms in the treatment of various diseases including fibrotic lung diseases.
· NXP002 Compositions for Treatment: Now in national filing stages and proceeding through examination.
NXP004
The Company’s NXP004 programme is focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca, under the Lynparza® brand name. On 14 June 2024 the US Patent and Trademark Office (“PTO”) has granted the Company patent number 12012386 covering the lead cocrystals under development, representing the first granted patent in this second NXP004 cocrystal series.
Dr Dan Gooding, Executive Director of Nuformix, said: “I’m delighted we’ve received these multiple grants of key patents underpinning both our NXP002 and NXP004 programmes. The European patent grant represents the last major territory to confirm protection of the novel drug forms enabling NXP002’s development as a potential novel IPF treatment. Granting of the method of use patent in the US further strengthens our IP position for this programme. The US PTO’s decision to grant the patent protecting the NXP004 programme’s lead cocrystals is also a first, with other territories soon to follow. The granting of these patents is very helpful and timely in progressing on-going discussions with potential development partners.”
